Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
High Tide ( (TSE:HITI) ) just unveiled an announcement.
High Tide Inc. has completed the acquisition of a 51% stake in Remexian Pharma GmbH for approximately €26.4 million, marking its expansion into the European cannabis market. This strategic move positions High Tide as a global cannabis company, diversifying its revenue base beyond Canada and paving the way for expansion across Europe’s regulated cannabis markets. The acquisition is expected to enhance High Tide’s long-term global leadership in the industry.
The most recent analyst rating on (TSE:HITI) stock is a Hold with a C$4.50 price target. To see the full list of analyst forecasts on High Tide stock, see the TSE:HITI Stock Forecast page.
Spark’s Take on TSE:HITI Stock
According to Spark, TipRanks’ AI Analyst, TSE:HITI is a Neutral.
High Tide’s overall stock score is driven by strong financial performance and positive earnings call sentiment, highlighting growth in retail expansion and market share. However, the technical indicators suggest the stock may be overbought, and the negative P/E ratio reflects ongoing profitability challenges.
To see Spark’s full report on TSE:HITI stock, click here.
More about High Tide
High Tide, Inc. is a leading cannabis enterprise focused on retail-forward operations, aiming to maximize the value of cannabis. Its subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. High Tide is uniquely built around the cannabis consumer, with diversified and integrated operations across all components of cannabis.
Average Trading Volume: 62,734
Technical Sentiment Signal: Buy
Current Market Cap: C$400.3M
For detailed information about HITI stock, go to TipRanks’ Stock Analysis page.